We are advised by Roche US that journalists and other readers shouldplease disregard the news release, New Study Demonstrates ACTEMRA(R)(tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid ArthritisPatients, issued earlier today over PR Newswire.
